•  
  •  
  •  
  •  

2025-12-21 09:17:36

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • South Indian Bank Introduces RuPay SIB Paytag
  • Nifty Bank reclaims 59,000 but lacks follow-through strength
  • Nifty Ends Four-Day Losing Streak on Strong Global Cues
  • HDFC SKY Expands MTF Universe with Addition of HDFC Gold ETF
  • Nifty breaks losing streak, but continues to trade in broader consolidation range

Keywords Selected:  INE203A01020

Stock Report

  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Datopotamab Deruxtecan powder
  • AstraZeneca Pharma India Ltd and Sun Pharma partner to help patients living with Hyperkalaemia in India
  • AstraZeneca Pharma India Ltd to launch Sodium Zirconium Cyclosilicate powder in Nov 2025
  • AstraZeneca Pharma India Ltd receives sale and distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder
  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Durvalumab Solution
  • AstraZeneca Pharma India Ltd surrenders marketing authorisation for Olaparib 100mg and 150mg
  • AstraZeneca Pharma India Ltd to discontinue the manufacturing and marketing of Imdur from April 1, 2025
  • AstraZeneca Pharma India Ltd receives permission for Olaparib film-coated tablets
  • AstraZeneca Pharma India Ltd to launch Breztri Aerosphere in January 2025 in India
  • AstraZeneca Pharma India Ltd to launch Tremelimumab
  • AstraZeneca Pharma India Ltd to launch Palivizumab in India
  • AstraZeneca Pharma India Ltd updates on exploring contract manufacturer
  • AstraZeneca Pharma India Limited achieves growth of 29% for financial year ended March 31, 2024
  • AstraZeneca Pharma India Ltd and Mankind Pharma partner to accelerate access to asthma medicine for patients in India
  • AstraZeneca Pharma India Ltd receives permission to import new drug
  • AstraZeneca Pharma India Ltd to launch Enhertu in January 2024
  • AstraZeneca Pharma India Ltd receives permission from CDSCO to import new drug
  • AstraZeneca Pharma India Ltd receives permission to Import pharmaceutical formulations of new drug for sale
  • AstraZeneca Pharma India receives permission to import Palivizumab solution for injection
  • AstraZeneca Pharma India Ltd receives permission from DCGI for Dapagliflozin Tablets 10 mg
  • AstraZeneca Pharma India Ltd receives permission for sale and distribution of Trastuzumab deruxtecan
  • AstraZeneca Pharma India receives permission for Dapagliflozin tablets
  • AstraZeneca Pharma India gets permission from DCGI for Olaparib Film-Coated tablets
  • AstraZeneca Pharma India Limited recommends final dividend of Rs. 8

Latest Post

  • South Indian Bank Introduces RuPay SIB Paytag
  • Nifty Bank reclaims 59,000 but lacks follow-through strength
  • Nifty Ends Four-Day Losing Streak on Strong Global Cues
  • HDFC SKY Expands MTF Universe with Addition of HDFC Gold ETF
  • Nifty breaks losing streak, but continues to trade in broader consolidation range


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024